Michael CFA - Rapid Micro Vice Communications
| RPID Stock | USD 1.11 0.03 2.78% |
Executive
Michael CFA is Vice Communications of Rapid Micro Biosystems
| Address | 1001 Pawtucket Boulevard West, Lowell, MA, United States, 01854 |
| Phone | 978 349 3200 |
| Web | https://www.rapidmicrobio.com |
Rapid Micro Management Efficiency
The company has return on total asset (ROA) of (0.2533) % which means that it has lost $0.2533 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4562) %, meaning that it created substantial loss on money invested by shareholders. Rapid Micro's management efficiency ratios could be used to measure how well Rapid Micro manages its routine affairs as well as how well it operates its assets and liabilities. As of November 22, 2024, Return On Tangible Assets is expected to decline to -0.38. In addition to that, Return On Capital Employed is expected to decline to -0.48. At present, Rapid Micro's Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Non Currrent Assets Other is expected to grow to about 1.2 M, whereas Other Assets are forecasted to decline to 0.95.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| John Ballard | Vivos Therapeutics | N/A | |
| Shana Zink | Treace Medical Concepts | N/A | |
| Matthew III | LivaNova PLC | N/A | |
| Helen Leupold | Bioventus | N/A | |
| John Webb | LivaNova PLC | N/A | |
| Frank Vizesi | Orthofix Medical | N/A | |
| Ruth Hembree | Vivos Therapeutics | N/A | |
| Mark Karshner | Orthopediatrics Corp | N/A | |
| Les DeLuca | Bluejay Diagnostics | N/A | |
| Aaron Berutti | Treace Medical Concepts | 45 | |
| MBA BS | Bioventus | N/A | |
| Maureen OConnell | Rxsight | N/A | |
| Albert Li | Owlet Inc | N/A | |
| Indranil Dey | Bluejay Diagnostics | 61 | |
| Ahmet Tezel | LivaNova PLC | N/A | |
| Eryn Graham | Bluejay Diagnostics | N/A | |
| Sean Scanlan | Treace Medical Concepts | 42 | |
| Harold Tamayo | Axogen Inc | N/A | |
| Julie Dewey | Treace Medical Concepts | 63 | |
| Ryan McSeveney | Bluejay Diagnostics | N/A | |
| CFA CPA | Axogen Inc | 50 | |
Management Performance
| Return On Equity | -0.46 | ||||
| Return On Asset | -0.25 |
Rapid Micro Biosystems Leadership Team
Elected by the shareholders, the Rapid Micro's board of directors comprises two types of representatives: Rapid Micro inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Rapid. The board's role is to monitor Rapid Micro's management team and ensure that shareholders' interests are well served. Rapid Micro's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Rapid Micro's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Robert Spignesi, President CEO | ||
| John Wilson, Chief Officer | ||
| Michael CFA, Vice Communications | ||
| Kristine Williams, Senior Management | ||
| Jonathan Paris, Gen VP | ||
| Sean CPA, Chief Officer | ||
| Victoria Vezina, Chief Officer | ||
| Michael Wysocki, Senior Marketing | ||
| James Xu, VP Secretary | ||
| Sean Wirtjes, Chief Officer |
Rapid Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Rapid Micro a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.46 | ||||
| Return On Asset | -0.25 | ||||
| Profit Margin | (1.85) % | ||||
| Operating Margin | (1.58) % | ||||
| Current Valuation | (7.9 M) | ||||
| Shares Outstanding | 37.72 M | ||||
| Shares Owned By Insiders | 8.53 % | ||||
| Shares Owned By Institutions | 57.65 % | ||||
| Number Of Shares Shorted | 70.42 K | ||||
| Price To Book | 0.55 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Rapid Micro Biosystems is a strong investment it is important to analyze Rapid Micro's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Rapid Micro's future performance. For an informed investment choice regarding Rapid Stock, refer to the following important reports:Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Rapid Micro Biosystems. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.
Is Wireless Telecommunication Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Rapid Micro. If investors know Rapid will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Rapid Micro listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.12) | Revenue Per Share 0.603 | Quarterly Revenue Growth 0.237 | Return On Assets (0.25) | Return On Equity (0.46) |
The market value of Rapid Micro Biosystems is measured differently than its book value, which is the value of Rapid that is recorded on the company's balance sheet. Investors also form their own opinion of Rapid Micro's value that differs from its market value or its book value, called intrinsic value, which is Rapid Micro's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Rapid Micro's market value can be influenced by many factors that don't directly affect Rapid Micro's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Rapid Micro's value and its price as these two are different measures arrived at by different means. Investors typically determine if Rapid Micro is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Rapid Micro's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.